A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Description

The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.

Conditions

Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.

A Phase II Adaptive Study of Local Ablative Therapy (LAT) for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Using Minimal Residual Disease (MRD) as an Integral Biomarker

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Condition
Non-small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Hartford

Hartford Healthcare ALLIANCE (Data collection only), Hartford, Connecticut, United States, 06102

Miami

BAPTIST ALLIANCE - MCI (Data collection only), Miami, Florida, United States, 33143

Basking Ridge

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * At the time of therapeutic phase enrollment, complete response radiographically (no lesions to target)
  • * Patients with CNS-only disease (due to limited capacity of peripheral blood ctDNA to detect CNS lesions)
  • * Planned treatment by targeted agents (e.g. tyrosine kinase inhibitors) or patient not a candidate for systemic therapy
  • * Serious medical co-morbidities precluding radiotherapy or ablation, determined at the discretion of the treating investigator.
  • * At the time of therapeutic phase enrollment, pregnant or lactating women.
  • * Physical limitation to undergo stereotactic radiotherapy.
  • * Other active malignancy within the last year except for basal cell carcinoma of the skin and in situ malignancy even if without evidence of disease.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Daniel Gomez, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2025-06-15